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Screening, and definitive diagnosis, of chromosomal abnormalities is an important part of obstetric care, fraught with emotional decisions and controversy. With technological advancements, new modalities for screening and diagnosis are being developed, which inherently produce a multitude of associated contentious issues. It is the obstetrician's duty to inform patients of their options for prenatal testing which are ever increasing in diversity with advanced research and technological improvements. Therefore, it is imperative for practitioners to remain informed about available options, as well as the potential associated controversies. Obtaining genetic material for analysis of fetal genetics was previously only possible via invasive procedures (CVS to obtain mesodermal connective tissue and placental trophoblast cells or amniocentesis to obtain amniotic fluid samples of mostly epithelial origin), with increased maternal and fetal risks (mainly miscarriage and infection).
However, after discovery of cell-free fetal DNA (cffDNA) in maternal serum in 1997, extensive research has led to the development of non-invasive prenatal testing (NIPT) for fetal aneuploidy screening 1 . Fetal DNA circulates in maternal blood in two forms, either as intact fetal cells or circulating cffDNA from the breakdown of mainly placental cells. Whilst "intact fetal cells can persist for years after a pregnancy, cell-free DNA clears from the maternal system quickly and is undetectable in maternal serum within hours of delivery 1, 2 . Thus cffDNA detected during a pregnancy is DNA considered to be representative of the current fetus. At present, NIPT is recommended solely for high-risk populations (i.e. advanced maternal age, abnormal serum screen, abnormal ultrasound, personal/family history of aneuploidy). However, there is interest surrounding whether the same validation data can be found to support testing in all populations, due to inconclusive data which is not currently supported by professional associations Supported by a commercial laboratory, the authors compared NIPT with traditional aneuploidy screening on a relatively small number of average risk women, introducing potentials for bias into the trial. According to the Society for Maternal and Fetal Medicine this "study was too small to compare detection rates, but the authors report that the false positive rate of NIPT is lower and therefore the test 'merits serious consideration as a primary screening method for fetal autosomal aneuploidy.'"
5
Additionally, many samples were obtained in the third trimester-when aneuploidy screening is not clinically relevant and fetal DNA assays are higher, which may account for improved test results 4 .
NIPT analyses cffDNA via a peripheral sample as early as ten weeks (typically between 10-22 weeks), but is still deemed to be a screening test 2 . Commercial laboratories employ differing methodologies for testing; however, "the overall reported performance is similar, with detection rates for Down syndrome above 99% and false positive rates that are <1%." Subsequently, women with positive results will require counselling regarding their individual risk, in order to discuss appropriate diagnostic testing to determine fetal DNA composition definitively 6 .
As demonstrated in the most recent CARE study in the New England Journal of Medicine, "using NIPT rather than conventional aneuploidy screening could potentially result in an 89% reduction in diagnostic procedures necessary to confirm a positive screen result." This will inherently reduce unnecessary invasive tests and hopefully diminish associated parental anxiety and stress. This study also has shown that NIPT "performs consistently well in all pregnant women, regardless of the a priori risk for fetal aneuploidy"
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. Sensitivity and specificity of NIPT is quoted at 99.9%; however, PPV and NPV will change depending upon background population risk. Therefore, if a woman in a high risk population has a prevalence of trisomy 21 of 5%, there will be a quoted risk of 1/20, her PPV is very high (4995/5000) ~98% 7 . Conversely, a woman in a low risk population (prevalence 0.1%), even with the same test sensitivity and specificity will have a much lower PPV of approximately 50% (100/200), which are crucial messages to explain to patients (table)   7 . Furthermore, the fetal fraction must be high enough to obtain an adequate sample, which can be influenced by maternal factors, especially obesity. Statistics for failure to obtain results range from 1-12%, which must be highlighted to patients, especially if in these certain demographic populations known to have increased risk of failure 6 . The conclusions proposed by Bianchi et al require extensive further investigation and data collection/analysis, with many study limitationsmainly being "underpowered to compare the detection rates and it is generally not valid to compare false-positive rates in isolation." 4 Additionally, false positive rates were only analysed for trisomies 18 and 21, without mention of trisomy 13 and sex chromosomes, which are also tested by commercial laboratories (with higher false positive rates) [8] [9] [10] . . Furthermore, sex aneuploidies are also now able to be screened with advanced technology by some companies; however, not all chromosomal anomalies (i.e. unbalanced translocations, deletions and duplications) will be detected. False-positive results can still occur; therefore, confirmatory invasive testing with CVS or amniocentesis is still recommended 12 . Patients must also be aware of false negative results, which cannot ensure an unaffected pregnancy. The benefits and impact of NIPT in rural communities have not been thoroughly researched; however, it is evident that travel and interruption to lifestyle are major factors to consider for these families when diagnostic testing is required. Furthermore, the extended "shelf-life" of these NIPT samples, which currently requires international testing, is an additional benefit for families in rural and remote communities, where potential logistical problems may arise due to geographical isolation [8] [9] [10] .
Another aspect fraught with controversy is the associated cost of testing. As technology develops, there is likely to be a reduction in out-of -pocket expense to patients. Presently, the cost for testing in Australia varies from $495-1000, depending upon the laboratory, which usually includes genetic counselling. Some insurance companies will partially subsidise this cost for women at risk. Yet with popularity and maternal age increasing, and women requesting 'reassurance' (with low-risk first CFTS or who do not meet testing criteria), there is an increased financial burden which must be considered. Nevertheless, in many circumstances, the reassurance and/or diagnosis received allows for definitive decisions, timing and planning to be made about the pregnancy which, for many couples, is priceless. Practitioners must broach the predicament of patient autonomy versus appropriate resource use with caution and supporting evidence.
RCOG concludes that "in time, this technology is likely to become the primary screen for chromosomal abnormalities in pregnancy." 13 . ACOG recommends that all women, 
